|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 860 WINTER STREET |
Address2 |
|
| City | WALTHAM |
State | MA |
Zip Code | 02451 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 23975-12
|
||||||||
|
6. House ID# 319670000
|
||||||||
| TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Lois Dehls Cornell, Executive Vice President |
Date | 1/18/2019 11:04:20 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Opioids
HR 6 - SUPPORT for Patients and Communities Act - Authorization for opioid prevention and treatment programs; PL 115-271
Increased funding for Medically Assisted Treatment in Correctional Facilities - no specific bill
Safe Injection Facilities - no specific bill
S.3428 - Lessening Addiction By Enhancing Labeling - (LABEL) Opioids Act
Increased funding and focus on the social determinants of health, including food - No specific bill
Opposition to proposed cuts to the Supplemental Nutrition Assistance Program - No specific bill
Separation of Immigrant Children From Their Families - No specific bill
Prescription Drug Prices
S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.
Efforts to address the cost of prescription drugs, including proposals to include the manufacturers suggested retail price in direct to consumer advertising of prescription drugs - no specific bill
Physician Burnout & Wellness - no specific bill
Gun Violence
HR 1832, S.834 - A bill to authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
S. 2546 - Making America Safe and Secure Act of 2018 - MASS Act
S. 1701 - Fair Access to Science and Technology Act - changes to copyright protections for publications
Changes to Sunshine Act Regarding Patient education materials - no specific bill
Regulatory Issues
Electronic medical records - efforts to streamline and improve interoperability
DEA issues
Updated regulations to implement Partial Fill law
Updated regulations for Eprescribing of Controlled Substances
Regulations
CMS - Comments to questions on Open Payments Program for educational materials
US Department of Homeland Security: Proposed rulemaking 8 CFR 103,8 CFR 212 to 214,8 CFR 248; RIN 1615-AA22; Inadmissibility on Public Charge Grounds,
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Opioids
HR 6 - SUPPORT for Patients and Communities Act - Authorization for opioid prevention and treatment programs; PL 115-271
Increased funding for Medically Assisted Treatment in Correctional Facilities: no specific bill
Safe Injection Facilities - no specific bill
S.3428 - Lessening Addiction By Enhancing Labeling - (LABEL) Opioids Act
Increased funding and focus on the social determinants of health, including food - No specific bill
Opposition to proposed cuts to the Supplemental Nutrition Assistance Program - No specific bill
Separation of Immigrant Children From Their Families - No specific bill
Prescription Drug Prices
S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.
Efforts to address the cost of prescription drugs, including proposals to include the manufacturers suggested retail price in direct to consumer advertising of prescription drugs - no specific bill
Physician Burnout & Wellness - no specific bill
Gun Violence
HR 1832, S.834 - A bill to authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
S. 1701 - Fair Access to Science and Technology Act - changes to copyright protections for publications
Changes to Sunshine Act Regarding Patient education materials - no specific bill
Regulatory Issues
Electronic medical records - efforts to streamline and improve interoperability
DEA issues
Updated regulations to implement Partial Fill law
Updated regulations for Eprescribing of Controlled Substances
Regulations
CMS - Comments to questions on Open Payments Program for educational materials
US Department of Homeland Security: Proposed rulemaking 8 CFR 103,8 CFR 212 to 214,8 CFR 248; RIN 1615-AA22; Inadmissibility on Public Charge Grounds,
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Opioids
HR 6 - SUPPORT for Patients and Communities Act - Authorization for opioid prevention and treatment programs; PL 115-271
Increased funding for Medically Assisted Treatment in Correctional Facilities: no specific bill
Safe Injection Facilities - no specific bill
S.3428 - Lessening Addiction By Enhancing Labeling - (LABEL) Opioids Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Drug Enforcement Administration (DEA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions.
Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIR
16. Specific lobbying issues
Gun Violence
HR 1832, S.834 - A bill to authorize the appropriation of funds to the Centers for Disease Control and Prevention for conducting or supporting research on firearms safety or gun violence prevention.
S. 2546 - Making America Safe and Secure Act of 2018 - MASS Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Separation of Immigrant Children From Their Families - No specific bill
US Department of Homeland Security: Proposed rulemaking 8 CFR 103,8 CFR 212 to 214,8 CFR 248; RIN 1615-AA22; Inadmissibility on Public Charge Grounds,
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Homeland Security - Dept of (DHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 1701 - Fair Access to Science and Technology Act - changes to copyright protections for publications
Changes to Sunshine Act Regarding Patient education materials - no specific bill
CMS - Comments to questions re Open Payments Program for educational materials
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Alexandra |
Calcagno |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |